Applicants: Short et al. Application No: 10/599,943 Amendment and Response

Docket No.: P-7735 (102-682 PCT/US)

Page 2

AMENDMENTS TO THE CLAIMS:

The following list of claims will replace all prior versions, and listings, of claims. Please amend the claims as follows:

- 1. (Currently Amended) A method for the selective disassociation of at least one biological entity from a plasma polymerized surface of an organic monomer <u>including an allylamine</u>, said method comprising:

 contacting said surface with at least one agent <u>having a salt concentration of about 100 mM NaCl to about 2 M NaCl</u>, wherein said agent provides for which either directly or <u>indirectly selective promotes</u> disassociation of said entity from said <u>plasma polymerized</u> surface.
- 2. (Original) A method according to Claim 1 wherein said biological entity is a carbohydrate.
- 3. (Original) A method according to Claim 2 wherein said carbohydrate is a homopolysaccharide.
- 4. (Original) A method according to Claim 2 wherein said carbohydrate is a heteropolysaccharide.
- 5. (Original) A method according to Claim 4 wherein said heteropolysaccharide is a glycosaminoglycan.
- 6. (Original) A method according to any of Claims 2-5 wherein said carbohydrate is a sulphated biomolecule.

Applicants: Short et al. Application No: 10/599,943 Amendment and Response

Docket No.: P-7735 (102-682 PCT/US)

Page 3

- 7. (Currently Amended) A method according to Claim 5 wherein said glycosaminoglycan is selected from the group consisting of: hyaluronan; dermatan sulfate; chondroitin sulphate; heparin; heparan sulphate; and or keratan sulphate.
- 8. (Original) A method according to Claim 1 wherein said biological entity is a polypeptide.
- 9. (Original) A method according to Claim 1 wherein said biological entity is a nucleic acid molecule.
- 10. (Previously presented) A method according to claim 9 wherein said nucleic acid molecule is selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and peptide oligonucleotides (PNAs).
- 11. (Original) A method according to Claim 1 wherein said biological entity is a cell or viral particle.
- 12. (Previously presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile acid.
- 13. (Previously presented) A method according to Claim 12 wherein said surface comprises at least 5% of said volatile acid.
- 14. (Previously presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile alcohol.
- 15. (Previously presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile amine.

Applicants: Short et al. Application No: 10/599,943 Amendment and Response

Docket No.: P-7735 (102-682 PCT/US)

Page 4

16. (Previously presented) A method according to Claim 1 wherein said surface comprises a mixture of volatile acid and volatile hydrocarbon.

17-25. (Cancelled).

26. (Previously presented) A method according to Claim 6 wherein said glycosaminoglycan is selected from the group consisting of: hyaluronan; dermatan sulfate; chondroitin sulphate; heparin; heparan sulphate; or keratan sulphate.

27. (Previously presented) A method according to claim 10 wherein said DNA is selected from cDNA, genomic DNA, single stranded DNA and oligonucleotides.

28. (New) A method according to claim 1, wherein said agent has a salt concentration of about 100 mM NaCl to about 1 M NaCl.

- 29. (New) A method according to claim 1, wherein said agent has a salt concentration of about 300 mM NaCl to about 1 M NaCl.
- 30. (New) A method according to claim 1, wherein said agent has a salt concentration of about 300 mM NaCl to about 500 M NaCl.
- 31. (New) A method according to claim 1, wherein said agent has a salt concentration of about 500 mM NaCl to about 750 mM NaCl.